Nashat Gabrail MD

Breast Cancer, Gynecologic Cancer, Hematologic Oncology

Gabrail Cancer Center

4875 Higbee Ave NWCanton, OH 44718
Phone+1 330-492-3345
Fax+1 330-492-0462

Dr. Gabrail is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gabrail's full profile Already have an account?

Summary

Founder of Gabrail Cancer Center. Active in clinical research and new anticancer drug development. Special interes in family cancer syndromes and cancer genetics.
Published the book "Good Medicine is Cheaper Medicine"

Education & Training

SSM Health/Saint Louis University School of MedicineFellowship, Hematology and Medical Oncology, 1987 - 1998
Hurley Medical Center/Michigan State UniversityResidency, Internal Medicine, 1985 - 1986
University of Mosul College of MedicineClass of 1976

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 1990 - 2027
NC State Medical License 2021 - 2022
IA State Medical License 2016 - 2020
MI State Medical License 1985 - 1998
MO State Medical License 1986 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013

Clinical Trials

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
UNKNOWN
PHASE4
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
TERMINATED
PHASE2
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
COMPLETED
PHASE2

Publications & Presentations

PubMed

Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.
Sarina A Piha-Paul, Chih-Yi Liao, Farshid Dayyani, Nashat Y Gabrail, Syed Mohammad Ali Kazmi
Clinical Cancer Research. 2026-07-23
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Matthew S Davids, Asher Chanan-Khan, Sikander Ailawadhi, Vladimir Ivanov, Ganna Usenko
Med. 2025-12-12
6 citations
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Timothy A Yap, David S P Tan, Anastasios Stathis, Geoffrey I Shapiro, Satoru Iwasa
Cancer Discovery. 2025-10-06

Abstracts/Posters

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Nashat Y. Gabrail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phleb...
Nashat Gabrail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCCJanuary 12th, 2022
Intravenous Iron Replacement Therapy for Iron Deficiency Anemia in AdultsJanuary 1st, 2022